Dr. Sighild Lemarchant, Axoltis Pharma – Head of Preclinical R&D, will participate to the 15th International Neurotrauma Symposium meeting 2022 organized by the INTS, which will take place in Berlin, Germany, on July 17-20, 2022. A preclinical proof of concept study showing that Axoltis’ peptide NX210c, which is now at clinical stage of development, represents a new promising drug candidate for the treatment of Spinal Cord Injury, will be presented by the lab of Pr. Michael Fehlings (University Health Network, Toronto, Canada).